Loxo Oncology is developing a pipeline of targeted oncology treatments, including those focused on cancers that can be detected by genomic testing. Last year, the FDA approved Loxo’s Vitrakvi, which proved to be effective against a variety of cancers caused by a rare genetic mutation.
“We’d like to grow our presence in oncology. We have a good set of medicines there, but we’d like to expand that because there’s so much exciting science for patients emerging in oncology to invest in,” Eli Lilly CEO David Ricks told CNBC.
The acquisition comes just a few days after Bristol-Myers Squibb announced plans to buy Celgene for $74 billion in cash and stock — one of the largest deals in pharma history.
More articles on pharmacy:
Hospital-owned drug company attracts 12 more health systems
How nurses are becoming integral to pharma marketing: 7 notes
4 tips for managing drug spend from Alameda Health System’s Dr. Yi-Chih Peng
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.